Research digest / the studies
The CJC-1295 Research, Study by Study
Four landmark studies, one mechanism, and the boundary where the human data run out.
The mechanism on the GH/IGF-1 axis
CJC-1295 binds the GHRH receptor — a class B G-protein-coupled receptor on anterior-pituitary somatotrophs — and activates Gs/cAMP/PKA signaling that drives GH gene transcription and pulsatile GH release [1][2]. The released GH then acts on hepatic GH receptors through JAK2/STAT5 to produce IGF-1, the downstream hormone that mediates most of GH's anabolic effects [1].
What makes CJC-1295 distinct from native GHRH is duration. Four substitutions confer resistance to dipeptidylpeptidase-IV and other degradation, and the DAC variant's albumin conjugation extends plasma residence to days, giving sustained GHRH-receptor stimulation from a single dose [2]. The research question that follows is whether that sustained stimulation flattens the natural pulse pattern of GH — and the published answer is that it does not [3].
What does the published human research on CJC-1295 actually show?
Limited early-phase PK work, and it is consistent. In healthy adults aged 21 to 61, single subcutaneous 30 or 60 micrograms per kilogram doses produced dose-dependent 2- to 10-fold rises in mean GH for six or more days and 1.5- to 3-fold rises in IGF-1 for nine to eleven days; after multiple doses IGF-1 stayed elevated up to 28 days, with a CJC-1295 half-life of 5.8 to 8.1 days [1]. That study (Teichman 2006) is the backbone of the human record, alongside a second PK study (Ionescu 2006) and a proteomic readout (Sackmann-Sala 2009) [3][4]. No large efficacy or long-term safety trial exists.
How quickly do GH and IGF-1 respond?
Fast, and for IGF-1, durably. In healthy men aged 20 to 40, a single subcutaneous CJC-1295 dose of 60 or 90 micrograms per kilogram raised basal GH approximately 7.5-fold and lifted mean GH by about 46% and IGF-1 by about 45% one week later [3]. The same study found that the frequency and magnitude of pulsatile GH secretion were unaltered — pulsatility persisted even under continuous GHRH-analog stimulation [3]. That preservation matters, because episodic GHRH delivery drives GH pulses more effectively than continuous infusion [6], so a long-acting analog that keeps the pulse is a non-trivial result.
How does CJC-1295 affect IGF-1 levels?
It raises them indirectly, by raising GH first. In the week-long readout, IGF-1 rose roughly 45% after a single 60-90 micrograms per kilogram dose [3], consistent with the sustained multi-day kinetics of the DAC form and the up-to-28-day IGF-1 elevation seen after multiple doses [1]. A separate proteomic study in 11 healthy young men found that CJC-1295 shifted the serum protein profile — decreasing apolipoprotein A1 and a transthyretin isoform, increasing an albumin fragment and immunoglobulin species — and that one of those signals correlated linearly with IGF-1, identifying candidate biomarkers of GH/IGF-1 axis activation [4].
The albumin-conjugate result
The foundational chemistry came first. A series of hGRF(1-29) analogs bearing a C-terminal maleimidopropionyl-lysine handle were screened; the lead, CJC-1295, combined four DPP-IV-protective substitutions with covalent bioconjugation to serum albumin and produced a 4-fold increase in GH area-under-the-curve over two hours versus unconjugated hGRF(1-29) in rats, with peptide detectable in plasma beyond 72 hours and enhanced in-vitro stability against dipeptidylpeptidase-IV [2]. That is the experiment that turned a short-acting GHRH fragment into a multi-day drug candidate, and it is read in detail on the CJC-1295 DAC page.
The animal proof-of-concept
Duration translated into biology in a knockout model. In GHRH-knockout mice, 2 micrograms of CJC-1295 given once every 24 hours fully normalized body weight and length, whereas dosing every 48 to 72 hours was progressively less effective; treatment also raised pituitary GH mRNA [7]. The finding establishes that the long-acting analog's once-daily schedule is sufficient to restore GH-axis-dependent growth in an animal that cannot make its own GHRH — a clean demonstration that the molecule does what its design intends, in a system where the readout is unambiguous.
Where CJC-1295 Sits Among GHRH Analogs
CJC-1295 belongs to a class that includes sermorelin (synthetic GHRH(1-29)) and tesamorelin (an FDA-approved GHRH analog for HIV-associated lipodystrophy) [8]. A 2025 Nature Reviews Endocrinology review synthesizes the pharmacology of GHRH and its synthetic analogues, describing receptor signaling, the rationale for long-acting design, and the therapeutic and investigational landscape of the class [8]. CJC-1295's place in that class is defined by its half-life: it is the long-acting member, distinguished from short-acting sermorelin chiefly by the DAC albumin-conjugation strategy. The within-class comparison is drawn out on CJC-1295 vs sermorelin.
CJC-1295 and Ipamorelin: The Two-Receptor (GHRH + GHRP) Rationale
The pairing rests on receptor separation, not on a trial. CJC-1295 binds the GHRH receptor; ipamorelin binds the ghrelin/GH-secretagogue receptor. Because ghrelin and GH secretagogues potentiate GHRH-induced GH release, combining a GHRH analog with a GHRP is expected to drive GH more than either alone, and the combined effect can be supra-additive in experimental systems [5].
What the literature does not contain is a controlled human efficacy trial of the specific CJC-1295/ipamorelin combination in healthy adults. The two-pathway model is well supported by receptor pharmacology; the fixed-dose "protocols" circulating online are not derived from that evidence, and this site reports the rationale without endorsing any regimen.
What is CJC-1295 ipamorelin?
It is the common research pairing of CJC-1295 (a GHRH analog) with ipamorelin (a selective GH secretagogue acting on the ghrelin/GHS receptor). The two-pathway combination is studied because the receptors are distinct and their GH-release effects can be supra-additive [5]. It is a research pairing with a mechanistic rationale, not an approved combination product, and no controlled human trial has established its efficacy in healthy adults.
Does CJC-1295 and ipamorelin work?
The rationale is mechanistic and sound; the direct efficacy data are missing. GHRH analogs and GHRPs act through distinct receptors and synergize, and secretagogues potentiate GHRH-induced GH release [5]. But there is no controlled-trial efficacy data for the specific pairing in healthy adults — the synergy is inferred from receptor pharmacology, not demonstrated in a clinical endpoint study of the combination itself.
What Does the Research Describe CJC-1295 Doing?
It describes biochemical changes, not promised outcomes. In study settings, CJC-1295 produced sustained multi-day rises in GH and IGF-1 with preserved GH pulsatility [1][3], a 4-fold GH-AUC increase over unconjugated peptide in rats [2], and normalized growth in GHRH-knockout mice [7]. Those are the measured effects in the published record. Effects on body composition, athletic performance, or aging in healthy humans are not established by controlled trials, and this digest does not claim them.
What to expect when taking CJC-1295?
In study settings, the measurable changes were biochemical: sustained multi-day rises in GH and IGF-1 with preserved GH pulsatility [1][3]. This describes research observations, not promised outcomes in any individual. The studies measured hormone levels and pharmacokinetics in small groups of volunteers over weeks — not long-term clinical results, and not effects on healthy people seeking body-composition change. CJC-1295 is unapproved, and nothing here should be read as a use instruction.